Entera Bio Ltd

ENTX

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    20

Stocks News & Analysis

stocks

Are investors missing the boat on this future ASX leader?

The market is underestimating the clear path to profitability.
stocks

ASX shares plunge but remain undervalued

Shares drop 17% after guidance is revised but we still see value.
stocks

Ask the analyst: Why have markets shunned APA Group?

Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.8015.00-0.18%
CAC 407,423.6715.030.20%
DAX 4020,271.33138.480.69%
Dow JONES (US)42,518.28221.160.52%
FTSE 1008,201.5422.65-0.28%
HKSE19,260.1740.390.21%
NASDAQ19,044.3943.71-0.23%
Nikkei 22538,444.5829.72-0.08%
NZX 50 Index12,943.5759.190.46%
S&P 5005,842.916.690.11%
S&P/ASX 2008,213.3017.70-0.22%
SSE Composite Index3,227.1213.82-0.43%

Market Movers